

In the Claims

Claims 1-10 (cancelled)

11. (Currently amended) A method for preventing clotting induced by contact with surfaces in an extracorporeal blood circuit ~~of~~ for a patient undergoing chronic, intermittent, extracorporeal blood treatment comprising administering for each treatment ~~to the patient or to the circuit~~ 0.001 to 10 mg of methyl O-(3,4-di-O-methyl-2,6-di-O-sulpho- $\alpha$ -D-glucopyranosyl)-(1 $\rightarrow$ 4)-O-(3-O-methyl-2-O-sulpho- $\beta$ -D-glucopyranosyl uronic acid)-(1 $\rightarrow$ 4)-O-(2,3,6-tri-O-sulpho- $\alpha$ -D-glucopyranosyl)-(1 $\rightarrow$ 4)-O-(3-O-methyl-2-O-sulpho- $\alpha$ -L-idopyranosyl uronic acid)-(1 $\rightarrow$ 4)-2,3,6-tri-O-sulpho- $\alpha$ -D-glucopyranoside or a salt thereof per kg body weight of the patient.

12. (Currently amended) A method for preventing clotting induced by contact with surfaces in an extracorporeal blood circuit ~~of~~ for a patient undergoing chronic, intermittent, extracorporeal blood treatment comprising administering for each treatment ~~to the patient or to the circuit~~ 0.30 to 30 mg of methyl O-(3,4-di-O-methyl-2,6-di-O-sulpho- $\alpha$ -D-

Attorney Docket Number 0 97277 US 01

glucopyranosyl)-(1-4)-O-(3-O-methyl-2-O-sulpho- $\beta$ -D-glucopyranosyl uronic acid)-(1-4)-O-(2,3,6-tri-O-sulpho- $\alpha$ -D-glucopyranosyl)-(1-4)-O-(3-O-methyl-2-O-sulpho- $\alpha$ -L-idopyranosyl uronic acid)-(1-4)-2,3,6-tri-O-sulpho- $\alpha$ -D-glucopyranoside or a salt thereof.

13. (Previously added) The method of claim 11, comprising administering a dodecasodium salt thereof.

14. (Previously added) The method of claim 12, comprising administering a dodecasodium salt thereof.

15. (Currently amended) A method for preventing clotting induced by contact with surfaces in an extracorporeal blood circuit ~~of~~ for a patient undergoing chronic, intermittent, extracorporeal blood treatment comprising administering for each treatment ~~to the patient or to the circuit~~ 0.001 to 10 mg of methyl O-(2,3,4-tri-O-methyl-6-O-sulpho- $\alpha$ -D-glucopyranosyl)-(1-4)-O-(2,3-di-O-methyl- $\beta$ -D-glucopyranosyl uronic acid)-(1-4)-O-(2,3,6-tri-O-sulpho- $\alpha$ -D-glucopyranosyl)-(1-4)-O-(2,3-di-O-methyl-

Attorney Docket Number O 97277 US D1

$\alpha$ -L-idopyranosyl uronic acid)-(1 $\rightarrow$ 4)-2,3,6-tri-O-sulpho- $\alpha$ -D-glucopyranoside or a salt thereof per kg body weight of the patient.

16. (Currently amended) A method for preventing clotting induced by contact with surfaces in an extracorporeal blood circuit ~~of~~ for a patient undergoing chronic, intermittent, extracorporeal blood treatment comprising administering for each treatment ~~to the patient or to the circuit~~ 0.30 to 30 mg of a methyl O-(2,3,4-tri-O-methyl-6-O-sulpho- $\alpha$ -D-glucopyranosyl)-(1 $\rightarrow$ 4)-O-(2,3-di-O-methyl- $\beta$ -D-glucopyranosyl uronic acid)-(1 $\rightarrow$ 4)-O-(2,3,6-tri-O-sulpho- $\alpha$ -D-glucopyranosyl)-(1 $\rightarrow$ 4)-O-(2,3-di-O-methyl- $\alpha$ -L-idopyranosyl uronic acid)-(1 $\rightarrow$ 4)-2,3,6-tri-O-sulpho- $\alpha$ -D-glucopyranoside or a salt thereof.

17. (Previously added) The method of claim 15, comprising administering a nonasodium salt thereof.

18. (Previously added) The method of claim 16, comprising administering a nonasodium salt thereof.